EMA Validates Two Applications for Daiichi Sankyo Triple Lipid-Lowering Drug
The European Medicines Agency validated two marketing authorization applications for Daiichi Sankyo's triple lipid-lowering drug.
Related stories
APi Group Reports Record Q3 Revenue, Raises 2026 Outlook
APi Group reported third-quarter 2026 net revenues of $2.554 billion, up 22.5% year over year, and net income of $114 million. Adjusted EBITDA rose 24.6% to $350 million; adjusted
M impact | EQUITY | Oct 29, 2026, 12:35 PM UTC
Guaranty Trust Holding Reports Third-Quarter Results
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Harley-Davidson Shares Slip After Q3 Results as Shipments Fall
Harley-Davidson shares slipped after its third-quarter results, which showed shipments fell.
M impact | EQUITY | Oct 29, 2026, 12:24 PM UTC
China Longyuan Power Q3 Net Profit Falls 57.84% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:24 PM UTC
Ameriprise Financial Posts Q3 Revenue of $5.19B
Ameriprise Financial reported Q3 total revenue of $5.19 billion, versus FactSet estimates of $5.10 billion.
M impact | EQUITY | Oct 29, 2026, 12:23 PM UTC
Yunda Holding Group Q3 Net Profit Rises 28.28% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:23 PM UTC